London Biotechnology Show

Directions Website Contact the business

London Biotechnology Show Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from London Biotechnology Show, Biotechnology company, Clarence Centre 6 St. George's Circus, London.

The London Biotechnology Show is Europe’s flagship biotechnology event, connecting global leaders across red biotech to accelerate innovation, partnerships, and investment shaping the future of healthcare and life sciences.

We are pleased to welcome Nuclide Therapeutics as a Startup Exhibitor at the London Biotechnology Show 2026.Nuclide Ther...
23/10/2026

We are pleased to welcome Nuclide Therapeutics as a Startup Exhibitor at the London Biotechnology Show 2026.

Nuclide Therapeutics is a biotechnology company developing next-generation radiotheranostics for therapy-resistant cancers. The company integrates molecular targeting technologies with diagnostic and therapeutic radionuclides to identify, monitor, and treat resistant tumour populations that survive standard therapies and drive relapse. By advancing precision radiotheranostics from discovery toward clinical development, Nuclide Therapeutics aims to deliver clinically meaningful and commercially scalable oncology products for patients with limited treatment options.

Connect with Nuclide Therapeutics and discover innovative solutions supporting the biotechnology and life sciences industry at the London Biotechnology Show 2026

Secure your FREE visitor pass: https://londonbiotechshow.com/register?t=delegate&utm_campaign=sm&utm_medium=social_media&utm_source=linkedin

We are pleased to welcome Dr James Duboff to the speaker lineup at London Biotechnology Show 2026.Dr James Duboff is a S...
23/10/2026

We are pleased to welcome Dr James Duboff to the speaker lineup at London Biotechnology Show 2026.

Dr James Duboff is a Strategic Partnerships Director at Genomics England. He is responsible for global genomic research partnerships with large Pharmaceutical and Biotechnology companies (the Discovery Forum), enabling Companies to access and work with the genomic and clinical data, along with additional data types and resources across Genomics England and the UK genomics ecosystem. This includes all forms of industry engagement, from managing their applications for ethical approval, through to co-development of genomic-based R&D projects and orchestrating multi-stakeholder collaborations with leading academic and clinical teams, as well as legal and commercial agreements.

Dr Duboff has experience in R&D management working in large multinational Pharmaceuticals (GSK) and consumer health (P&G) companies. He has an Undergraduate-Masters in Molecular & Cellular Biochemistry from the University of Oxford and a PhD in Genetics from the University of Cambridge.

To hear from Dr James Duboff alongside leading voices from across the life sciences industry, secure your Delegate Pass:

https://londonbiotechshow.com/register?t=delegate&utm_campaign=sm&utm_medium=social_media&utm_source=linkedin

We are pleased to welcome Sciad Communications as a Media Partner for the London Biotechnology Show 2026.Sciad is a spec...
22/10/2026

We are pleased to welcome Sciad Communications as a Media Partner for the London Biotechnology Show 2026.

Sciad is a specialist marketing communications agency with a focus on science, technology, and healthcare.

Its talented team of strategists, digital marketers, communicators and creatives understand complex science, working together to create marketing campaigns and brands that create measurable impact.

Meet Sciad at Stand A7 and explore the latest conversations shaping biotechnology and life sciences at London Biotechnology Show 2026 this November.

Secure your Free Pass: https://londonbiotechshow.com/register?t=delegate&utm_campaign=sm&utm_medium=social_media&utm_source=linkedin

We are pleased to welcome Jürgen Riedel, PhD, founder of Baïomics, to the speaker lineup at London Biotechnology Show 20...
21/10/2026

We are pleased to welcome Jürgen Riedel, PhD, founder of Baïomics, to the speaker lineup at London Biotechnology Show 2026.

His work explores how AI and generative AI can support consequential decisions while preserving evidence, traceability, reliability and meaningful human judgement. He has worked across regulated healthcare AI, financial compliance, decision intelligence and complex data-driven systems, combining analytical discovery with research-led prototyping. Alongside his commercial work, Jürgen conducts independent research in computational biology and intelligent systems. His current interests include evaluating AI-assisted reasoning, provenance-aware architectures, and how emerging AI systems can contribute responsibly to biomedical and clinical decision-making.

To hear from Jürgen Riedel alongside leading voices from across the life sciences industry.

Secure your Delegate Pass: https://londonbiotechshow.com/register?t=delegate&utm_campaign=sm&utm_medium=social_media&utm_source=linkedin

We are pleased to welcome Siolta Therapeutics as a Conference Session Sponsor at the London Biotechnology Show 2026.Siol...
20/10/2026

We are pleased to welcome Siolta Therapeutics as a Conference Session Sponsor at the London Biotechnology Show 2026.

Siolta Therapeutics is a clinical-stage biotech company pioneering a new class of biologics, known as live biotherapeutic products (LBPs). By developing these microbial medicines to target immune modulation, a root cause of many chronic and inflammatory diseases, the company aims to prevent allergic diseases beginning with atopic dermatitis and food allergies.

The company’s lead asset, STMC-103H, has completed a successful Phase 2 trial (ADORED, n=238) in infants with familial history of allergic disease, reducing the odds of atopic dermatitis by 64% and food allergy by 77% vs. placebo at one year. Two-year data now demonstrates the effects of STMC-103H are sustained across the atopic march a full year after treatment completion. STMC-103H holds FDA Fast Track Designation and is positioned as a potential first-in-class biologic to prevent allergic disease(s) in at-risk infants advancing towards a pivotal Phase 3 study to address a large unmet market.

In addition to its lead program, Siolta has established scalable LBP manufacturing capabilities and holds a large, diverse biobank supporting pipeline expansion. The company is currently raising capital to fund Phase 3 development and BLA filing with committed insiders, strategic institutional interest, and significant support from NIAID.

Connect with Siolta Therapeutics at the London Biotechnology Show 2026.

Secure your FREE visitor pass: https://londonbiotechshow.com/register?t=delegate&utm_campaign=sm&utm_medium=social_media&utm_source=linkedin

We are pleased to welcome Linear Clinical Research as an exhibitor at the London Biotechnology Show 2026.Linear Clinical...
19/10/2026

We are pleased to welcome Linear Clinical Research as an exhibitor at the London Biotechnology Show 2026.

Linear Clinical Research is an Australia-based early-phase clinical trial organisation supporting global biotechnology, pharmaceutical and CRO partners across healthy volunteer, first-in-human, first-in-patient and early patient studies.

Operating from three purpose-built facilities in Perth, the organisation conducts clinical trials across oncology, haematology, immunology, cardiometabolic disease, vaccines and other outpatient populations. Its integrated site network includes a dedicated Early Phase Unit, the patient-focused Advanced Clinical Trials Centre and B-Block, a flexible facility designed for vaccine, confinement and outpatient studies.

Linear Clinical Research has conducted more than 500 healthy volunteer studies, with over 94% of cohorts dosed on time since the beginning of 2025. Its capabilities allow sponsors to progress from early-phase development into Phase 1b/2a and later-phase patient studies within one organisation.

As a not-for-profit organisation, Linear Clinical Research takes a high-touch, selective approach, with profits reinvested into its facilities, people and research capabilities to support consistently high-quality trial delivery.

Connect with Linear Clinical Research at the London Biotechnology Show 2026 and discover its capabilities in advancing early-phase clinical research and drug development.

Secure your FREE visitor pass: https://londonbiotechshow.com/register?t=delegate&utm_campaign=sm&utm_medium=social_media&utm_source=linkedin

1 Month To Go For London Biotechnology Show!The countdown to London Biotechnology Show 2026 is on. In just one month, th...
18/10/2026

1 Month To Go For London Biotechnology Show!

The countdown to London Biotechnology Show 2026 is on. In just one month, the life sciences community will come together to explore emerging breakthroughs, exchange expertise and discover new opportunities for innovation.

Taking place at ExCeL London, the event will connect biotech companies, pharmaceutical leaders, researchers, investors and healthcare innovators to foster collaboration and advance scientific progress.

Be part of the conversations shaping the next chapter of biotechnology. Register for your FREE PASS: https://londonbiotechshow.com/register?t=delegate&utm_campaign=sm&utm_medium=social_media&utm_source=linkedin

We are pleased to welcome GenSensor as a Startup Exhibitor at the London Biotechnology Show 2026.Between two manual samp...
16/10/2026

We are pleased to welcome GenSensor as a Startup Exhibitor at the London Biotechnology Show 2026.

Between two manual samples, a bioreactor can be a black box. GenSampler changes that. Connected directly to bioreactors, it draws samples on demand or on schedule, day and night, across several vessels in parallel. Each sample is prepared and stabilized inside the device, preserving the biological signal and turning a handful of manual time points into a detailed, reliable timeline of the run.

GenSensor then goes beyond sampling. Through mRNA biomarkers, AI-powered analytics and expert interpretation, it reveals how cells respond to process conditions, what genuinely drives yield, and when and why a culture begins to drift.

The result is faster process development, better-informed scale-up and tech transfer, and more effective troubleshooting across biopharma and precision fermentation.
Whether the cells are producing proteins, vaccines, advanced therapies or bio-based ingredients, GenSampler and GenSensor help researchers understand what the cells are actually doing.

Connect with GenSensor and discover innovative solutions supporting the biotechnology and life sciences industry at the London Biotechnology Show 2026.

Secure your FREE visitor pass: https://londonbiotechshow.com/register?t=delegate&utm_campaign=sm&utm_medium=social_media&utm_source=linkedin

We are pleased to welcome Dr Tim Hardman to the speaker lineup at London Biotechnology Show 2026.Dr Tim Hardman is Found...
15/10/2026

We are pleased to welcome Dr Tim Hardman to the speaker lineup at London Biotechnology Show 2026.

Dr Tim Hardman is Founder and Managing Director of Niche Science & Technology Ltd., the UK-based CRO he established in 1998 to provide tailored, science-driven support to pharmaceutical and biotech companies. With more than 25 years’ experience in clinical research, he has built Niche into a trusted early-phase development partner for start-ups and established companies worldwide.

Tim is Chairman of the Association of Human Pharmacology in the Pharmaceutical Industry (AHPPI) and a Board member and former President of EUFEMED (2021–2023). He also contributes to the Pharmaceutical Contract Management Group (PCMG) and holds an honorary fellowship at St George’s Medical School. He regularly comments on clinical research, regulatory innovation and AI.

To hear from Dr Tim Hardman alongside leading voices from across the life sciences industry, secure your Delegate Pass: https://londonbiotechshow.com/register?t=delegate&utm_campaign=sm&utm_medium=social_media&utm_source=linkedin

We are pleased to welcome India Pharma Outlook as a Media Partner for the London Biotechnology Show 2026.India Pharma Ou...
14/10/2026

We are pleased to welcome India Pharma Outlook as a Media Partner for the London Biotechnology Show 2026.

India Pharma Outlook is a business magazine focusing on the pharmaceutical industry in India. Having made its mark in the global market, the Indian pharmaceutical industry is a major contributor to the global pharma manufacturing and supply ecosystem. Being the largest supplier of generic medications in the world, the country is responsible for 20 percent of the worldwide supply by volume. It also undertakes around 60 percent of the global vaccination demand.
India Pharma Outlook strives to be the most credible source of industrial information pertaining to the pharma sector in the country. The magazine brings to you the stories of innovative pharma companies that are bringing about a positive change in the industry. From industry leaders to startups and SMEs, India Pharma Outlook presents a wholesome dose of information to keep you abreast of the latest advancements in the pharma segment.

Explore the latest conversations shaping biotechnology and life sciences at London Biotechnology Show 2026 this November.

Secure your Free Visitor Pass: https://londonbiotechshow.com/register?t=delegate&utm_campaign=sm&utm_medium=social_media&utm_source=linkedin

Address

Clarence Centre 6 St. George's Circus
London

Website

Alerts

Be the first to know and let us send you an email when London Biotechnology Show posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to London Biotechnology Show:

Shortcuts

Share

Category